A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors

Authors
Category Primary study
JournalCancer Research
Year 2012
This article has no abstract
Epistemonikos ID: 7db3afc05b60475552e0ea5ebe1ebaa646d78e60
First added on: Feb 05, 2025